WAY-100635

WAY-100635 is a potent and selective 5-HT1A Receptor antagonist with a pIC50 of 8.87, an apparent pA2 of 9.71. WAY-100635 is a potent and selective 5-hydroxytryptamine 1A (5-HT1A) receptor antagonist with an IC50 value of 0.91 nM and Ki value of 0.39 nM. WAY-100635 has pIC50 values for 5-HT1A and α1-adrenergic receptors of 8.9 and 6.6, respectively. WAY-100635 is also a potent dopamine D4 receptor agonist[1][2][3].

Product Specifications

CAS Number

[162760-96-5]

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/way-100635.html

Purity

99.44

Solubility

DMSO : 66.67 mg/mL (ultrasonic)

Smiles

O=C(N(C1=NC=CC=C1)CCN2CCN(CC2)C3=CC=CC=C3OC)C4CCCCC4

Molecular Formula

C25H34N4O2

Molecular Weight

422.56

References & Citations

[1]Chemel BR, et al. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) . 2006 Oct;188 (2) :244-51.|[2]Mannucci C, et al. Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats. Phytomedicine. 2012 Sep 15;19 (12) :1117-24.|[3]Al Hussainy R, et al. Design, synthesis, radiolabeling, and in vitro and in vivo evaluation of bridgehead iodinatedanalogues of N-{2-[4- (2-methoxyphenyl) piperazin-1-yl]ethyl}-N- (pyridin-2-yl) cyclohexanecarboxamide (WAY-100635) as potential SPECT ligands for the 5-HT1A receptor. J Med Chem. 2011 May 26;54 (10) :3480-91.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

5-HT1 Receptor; D4 Receptor; mLAG-3

Citation 01

Biomedicines. 2025 Sep 23;13 (10) :2319.|Chin J Integr Med. 2021 Jul;27 (7) :534-541.|Chin Med. 2024 Jun 15;19 (1) :87.|Int Immunopharmacol. 2024 Feb 15:128:111524.|iScience. 2025 Nov 25;28 (12) :114211.|Nat Neurosci. 2022 Jan;25 (1) :39-49.|Psychopharmacology (Berl) . 2022 Nov;239 (11) :3551-3565.|Psychopharmacology (Berl) . 2024 Nov;241 (11) :2315-2330.